Retatrutide Dosage Guide
Clinical Trials
FM
Reviewed by Fat Man in the Arena · Updated March 2026
Not medical advice. Dosage information is provided for educational purposes based on published research. Always consult a qualified healthcare provider before starting any protocol. Full disclaimer.
Dosage overview
| Typical dose | 1 mg to 12 mg weekly (Phase 2 doses) |
| Frequency | Once weekly subcutaneous injection |
Dosing notes
Not yet FDA-approved. Dosing based on Phase 2 trial data. Phase 3 trials are underway with results expected in 2026.
Important safety information
Dosage ranges listed above are based on available research data and reported protocols. Individual dosing should be determined by a qualified healthcare provider based on your specific health profile, goals, and response to treatment.
- Start at the lowest effective dose and titrate up gradually
- Monitor for side effects, especially during dose increases
- Do not exceed researched dose ranges without medical supervision
Research references
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity (Phase 2) — New England Journal of Medicine (2023) [PubMed]
Weekly peptide research updates
New studies, GLP-1 news, protocol insights, and weight loss data — delivered every week. Free. No spam.